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Abstract: Bisphosphonates are the major treatment of choice for osteoporosis, given that they 
are attached preferentially by bone and significantly reduce the risk of fractures. Oral bisphos-
phonates are poorly absorbed (usually less than 1% for nitrogen-containing bisphosphonates) and 
when taken with food or beverages create complexes that cannot be absorbed. For this reason, 
they must be taken on an empty stomach, and a period of up to 2 hours must elapse before the 
consumption of any food or drink other than plain water. This routine is not only inconvenient 
but can lead to discontinuation of treatment, and when mistakenly taken with food, may result 
in misdiagnosis of resistance to or failure of treatment. The development of an enteric-coated 
delayed-release formulation of risedronate with the addition of the calcium chelator, ethylene-
diaminetetraacetic acid (EDTA), a widely used food stabilizer, eliminates the need for fasting 
without affecting the bioavailability of risedronate or its efficacy.
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Introduction
Bone loss resulting from unbalanced bone remodeling that favors bone resorption is 
a major feature of common bone pathologies, such as osteoporosis, Paget’s disease, 
and metastatic bone disease. In most cases, antiresorptive treatment helps to lower 
excessive resorptive activity to a level that better equates to bone formation and thus 
reduces the risk of fractures. Bisphosphonates are among the most effective and 
widely used antiresorptive agents available.1 An important and unique advantage of 
bisphosphonates is their selective uptake by the skeleton, coupled with preferential 
targeting of sites with increased bone activity. Oral formulations, however, are poorly 
absorbed (on average usually less than 1%), and concomitant intake of food or bever-
age further limits absorption. For this reason, patients treated with oral bisphospho-
nates are advised to refrain from oral intake (other than plain water) for up to 2 hours 
following administration of medication. However, it has been found that more than 
half of patients may ignore these directives.2
The overall low oral bioavailability of bisphosphonates, together with the incon-
venient routine of keeping the stomach empty for a considerable amount of time, led 
to the development and success of weekly and monthly regimens, and now to the 
development of a once-weekly regimen utilizing risedronate 35 mg delayed-release 
(DR), to which the well known chelating compound ethylenediaminetetraacetic acid 
(EDTA) has been added. This allows patients the option to take the tablet before or 
following a meal. This regimen has been approved in the US for administration after 
a meal as a new drug (due to the addition of EDTA) under the brand name Atelvia®, 
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and in Canada as Actonel DR®, whilst in Australia it has 
been licensed as Actonel EC® (enteric-coated tablets) for 
administration before and after breakfast.
Structure and pharmacology  
of bisphosphonates
Bisphosphonates are chemical compounds with a high affin-
ity for bone mineral and therefore bind tightly to the exposed 
mineral surfaces of bone. At sites of bone formation, the newly 
deposited bisphosphonate becomes buried when additional 
bone is deposited on top. During the process of bone resorption, 
osteoclasts on the bone surface release acid and enzymes that 
resorb the mineralized matrix. In bisphosphonate-coated bone, 
osteoclasts encounter the chemical compound and ingest it, 
leading to their inactivation and possible death by apoptosis.3
Bisphosphonates are modified analogs of inorganic 
pyrophosphate structures where the oxygen connecting the 
two phosphate groups (P-O-P) is replaced by a carbon atom 
(P-C-P), as shown in Figure 1.4 As a result, bisphospho-
nates are resistant to chemical and enzymatic degradation. 
The addition of nitrogen in their structure (N-BPs) enhances 
their binding affinity and antiresorptive potency. Non-N-BPs, 
such as tiludronate, are little used today, whereas etidronate 
and clodronate are still sometimes prescribed to patients with 
osteoporosis or metastatic bone disease, respectively. The 
N-BPs in oral (alendronate, risedronate, ibandronate) or par-
enteral (intravenous) preparations (ibandronate, pamidronate, 
and zoledronate) act on the same pathway, ie, the mevalonate 
pathway, as the cholesterol-lowering drugs (statins) albeit 
downstream (Figure 2).4 They inhibit the farnesyl pyrophos-
phate synthase enzyme, thereby preventing prenylation (lipid 
modification) of many small GTPases, such as Ras, Rab, Rho, 
and Rac, a large group of signaling proteins that are critical 
for the function and survival of osteoclasts.3
Bisphosphonates  
reaching osteoclasts
enteric absorption of bisphosphonates
Oral formulations, especially the N-BPs, are poorly absorbed 
(∼1%)5 and their bioavailability may be negligible if taken 
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Figure 1 Bisphosphonate structure, bone mineral binding, and biochemical mechanisms.
Note: Reproduced from Pazianas M, Compston J, Huang CL-H. Atrial fibrillation and bispho sphonate therapy. J Bone Miner Res. 2010;25:2–10.4 With permission of the 
american Society for Bone and Mineral Research.
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on a full stomach. This may be due to the formation of 
insoluble chelates with elements such as calcium, magne-
sium, and aluminum, which are naturally present in many 
foods and liquids, but other mechanisms may be important. 
For these reasons, bisphosphonates must be taken before 
breakfast, with no subsequent food/beverage intake for at 
least 30 minutes and often longer. At the other end of the 
spectrum, commonly used medications such as proton pump 
inhibitors, which work by reducing the secretion of gastric 
acid, effectively elevate gastric pH, and may have the effect of 
increasing bisphosphonate bioavailability.6,7 Although some 
non-N-BPs can be metabolized intracellularly to cytotoxic 
adenosine triphosphate analogs, in general bisphos phonates 
are excreted in the urine unmetabolized. Moderate or severe 
renal impairment therefore may increase plasma concentra-
tions, and their use is not recommended in patients with 
creatinine clearance less than 30 mL per minute.
Our current understanding is that bisphosphonates are 
likely to be absorbed throughout the intestine, although 
more effectively in segments with comparatively larger 
surface areas (jejunum .duodenum .ileum).8 Studies 
using pamidronate and tiludronate on human intestinal 
epithelial CaCo-2 cells9,10 and alendronate in a rat model8 
suggest that bisphosphonates find their way into the systemic 
circulation through the paracellular and not the transcel-
lular route (Figure 3). More specifically, bisphosphonates 
reach the bloodstream through the tight junctions connect-
ing epithelial cells and pores permeable to molecules up 
to a molecular weight of 150. Bisphosphonates, however, 
are in the 200–400 molecular weight range, which limits 
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Figure 3 Paracellular, transcellular route, and tight junctions.
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Figure 2 Inhibition of the mevalonate pathway by statins and bisphosphonates.
Note: Reproduced from Pazianas M, Compston J, Huang CL-H. Atrial fibrillation and bispho sphonate therapy. J Bone Miner Res. 2010;25:2–10.4 With permission of the 
american Society for Bone and Mineral Research.
Abbreviation: HMG Co-a, 3-hydroxy-3-methylglutarylcoenzyme a. 
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effective absorption.11,12 Additionally, divalent ions, such 
as calcium and magnesium, are crucial for the function of 
tight junctions. Divalent cations bind strongly to all bispho-
sphonates, including N-BPs, and form chelates. Further, the 
lack of transcellular crossing coupled with the considerable 
hydrophobicity of the lining of the small intestine (and gastric 
and colonic mucosa) serves as a further limiting factor to the 
absorption of hydrophilic oral N-BPs, such as alendronate 
and risedronate.
Bisphosphonate uptake by osteoclasts
Osteoclasts ingest bisphosphonates via fluid phase endocy-
tosis, while two other modes of uptake, ie, adsorptive and 
receptor-mediated endocytosis, are probably not involved.13 
This fluid phase endocytosis is a low-efficiency and nonspe-
cific process characterized by bulk uptake of solutes in exact 
proportion to their concentration in extracellular fluid.14
Fasting and its effects on adherence 
(persistence/compliance)
Using the concepts of persistence (how long a patient contin-
ues therapy), compliance (how correctly, in terms of dose and 
frequency, a patient takes the medication), and adherence (a 
combination of persistence and compliance),15 it is possible 
to quantify their impact on treatment outcomes. Generally, the 
adherence rate for prescribed medications could be as low as 
0%, with an average of 50% for medications used in several 
chronic diseases.16 Low adherence could be mischaracterized 
as treatment failure and could lead to unnecessary and poten-
tially harmful treatment modifications.17
Interestingly, improving adherence does not increase the 
incidence of adverse events.18 In the case of osteoporosis, 
where the condition is asymptomatic and medication is taken 
primarily to prevent long-term skeletal complications, it has 
been estimated that one third to one half of patients do not 
take their medication as directed, and nonadherence may 
begin soon after treatment initiation.15 Even in countries 
reporting relatively good persistence with osteoporosis 
treatment, the mean persistence on oral bisphosphonates is 
only about 3 years.19
Treatment response is related to the dosage and admin-
istration of a therapy. The need to fast has been identified 
among the top three issues reported by patients as the reason 
for poor adherence20 (Figure 4). The inconvenience is obvious 
because overnight fasting prior to taking the medication and 
continuing for up to 2 hours afterwards could severely disrupt 
daily routines. Therefore, development of a formulation that 
would allow the patient to take the medication following 
breakfast is expected to improve adherence.21
Overcoming the fasting hurdle
Prevention of bisphosphonates from forming insoluble 
complexes with calcium and other divalent or trivalent 
cations present in food was found to be key to overcoming 
the fasting requirement. Therefore, use of chelating agents 
such as EDTA, which is commonly used as an antidote to 
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Figure 4 Fasting has been identified as one of the three main reasons for discontinuing treatment.
Note: Reproduced with permission from International osteoporosis Foundation. The adherence gap: why osteoporosis patients don’t continue with treatment.20
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metal toxicity22 in humans and extensively as a preservative 
in foods,23 has been explored.
Like bisphosphonates, chelating agents such as EDTA are 
poorly absorbed. Of orally consumed EDTA, for example, 
only 5% or less is absorbed and is almost entirely excreted 
unchanged in the urine (95%) within 72 hours.24 The low 
bioavailability of EDTA, however, becomes advantageous 
when a local but not systemic effect is desired. Indeed, coad-
ministration of EDTA with an oral bisphosphonate could 
ensure that calcium and other divalent or trivalent cations 
present in the food would be preferentially bound by the 
chelating agent and not by the bisphosphonate.
Furthermore, EDTA could enhance permeability by acting 
as a chelator of tight junction calcium ions, thereby widening 
the paracellular tight junctions, resulting in better absorption of 
bisphosphonate. This concept was tested in the early 1990s.25 
Alendronate or clodronate were given subcutaneously or by 
mouth together with EDTA in aqueous solution at neutral pH 
in a rat model of hypercalcemia. Absorption was increased by 
about ten-fold in animals treated with 0.6 mg/kg alendronate 
and decreased to two-fold with lower doses. The minimal 
effective dose for EDTA was estimated at 10 mg/kg for the 
alendronate-treated animals and 100 mg/kg for those treated with 
clodronate. However, the amount of EDTA required to achieve 
these increases was deemed clinically unacceptable.25
Today, we are able to use amounts of EDTA that are effec-
tive and clinically safe following the development of a tablet 
that protects the drug from gastric release and allows relatively 
rapid release in the small intestine (pH .5.5), where the con-
centrations of calcium and other divalent or trivalent cations 
are anticipated to be lower than in the fed stomach. Therefore, 
the amount of EDTA required to bind free cations present in 
the region of drug release should be less. This advance led to 
the development of an oral, once-weekly 35 mg risedronate 
DR formulation with a pH trigger of 5.5, combined with 
100 mg EDTA. The lag time (time for initial tablet opening) 
is usually 10 minutes and not more than 15 minutes. Dissolu-
tion is mostly complete (.95%) at 45 minutes. The coating 
of the tablet withstands prolonged exposure (16 hours) up to 
pH 5.0, thus preventing premature release in the stomach in 
cases of prolonged gastric retention and/or increased gastric 
pH. Further, the disintegration time is 4–12 times longer for 
the DR tablet than for the immediate-release (IR) tablet, and 
thus the potential would be less for disintegration of the DR 
tablet within the esophagus, where the environment is neutral, 
if transit time is delayed leading to esophageal exposure to 
risedronate. In this new formulation, the bioavailability of the 
risedronate 35 mg DR tablet is not markedly affected by the 
type of food administered at breakfast (typical or high-fat). 
The time to peak concentration for the 35 mg risedronate DR 
formulation tablet is ∼3 hours when administered in the morn-
ing 4 hours prior to a meal. Its bioavailability is decreased 
by ∼30% when administered after a high-fat breakfast, but 
is still similar or 2–4-fold greater when compared with the 
35 mg IR tablet administered 30 minutes prior to a high-fat 
breakfast. It is worth adding that when both formulations 
were administered after an overnight fast and followed by a 
4-hour fast, systemic exposure for the 35 mg DR formulation 
was approximately 44% greater than that for the 35 mg IR 
formulation (data on file, Procter & Gamble, 2009).
Plasma protein binding of risedronate in humans averages 
about 24%. Approximately 60% of the dose is distributed to 
bone and the remainder of the dose is excreted in the urine. 
The renal clearance is not concentration-dependent, and there 
is a linear relationship between renal and creatinine clearance. 
The renal clearance of risedronate was decreased by about 
70% in patients with a creatinine clearance of approximately 
30 mL per minute as compared with persons with normal 
renal function. The 35 mg risedronate DR formulation is not 
recommended for use in patients with severe renal impair-
ment (creatinine clearance less than 30 mL per minute), 
but no dose adjustment is necessary for higher creatinine 
clearances. Also, dosage adjustment is unlikely to be needed 
in patients with hepatic impairment. Unabsorbed drug is 
eliminated unchanged in feces.26
The risedronate 35 mg DR once-weekly tablet also con-
tains 100 mg EDTA. This is less than the acceptable daily 
intake (2.5 mg/kg as the calcium, disodium salt, which equates 
to 149 mg/day for a 60 kg person). It is expected to sequester 
a relatively small amount of calcium (approximately 10 mg) 
from the gastrointestinal tract. There is also no impact on 
solubility, and hence the absorption of coadministered drugs. 
Further, in patients treated with risedronate 35 mg DR imme-
diately following a standard meal and a proton pump inhibitor 
such as omeprazole or 600 mg calcium/400 IU vitamin D 
supplement, the bioavailability of risedronate was similar to 
that of the 35 mg IR tablet given at least 30 minutes before 
breakfast (data on file, Procter & Gamble, 2009). However, 
gastric acid-suppressive agents (antacids), calcium supple-
ments, magnesium-based supplements or laxatives, and iron 
preparations should be taken at a different time of the day.26
Clinical data: once a week  
risedronate 35 mg DR
A randomized, double-blind, active-controlled, parallel-
group study assessed the safety and efficacy of risedronate 
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Figure 5 Mean percent change from baseline ± standard error of the mean in (A) bone mineral density and (B) bone turnover markers over 2 years in women receiving 
risedronate 5 mg immediate-release daily (solid lines with black circles), 35 mg delayed-release immediately following breakfast weekly (dashed lines with black squares), or 
35 mg delayed-release at least 30 minutes before breakfast weekly (circle dashed lines with black triangles). Asterisk represents statistically significant difference between 
immediate-release daily and delayed-release weekly treatment group.
Note: With kind permission from Springer Science+Business Media: McClung MR, Balske a, Burgio De, Wenderoth D, Recker RR. Treatment of postmenopausal osteoporosis 
with delayed-release rise dronate 35 mg weekly for 2 years. Osteoporos Int. 2013;24:301–310.29
Abbreviations: CTX, C-terminal telopeptide; Se, standard error of the mean; CR, creatinine; BaP, bone alkaline phosphatase.
0
−10
−20
−30
−40
−50
−60
Baseline Week 13 Week 26 Week 52
Visit
Urine NTX/Cr
M
ea
n
 p
er
ce
n
t 
ch
an
g
e 
fr
o
m
b
as
el
in
e 
± 
S
E
Week 104 Endpoint
B
0
−10
−20
−30
−40
−50
−60
Baseline Week 13 Week 26 Week 52
Visit
Serum CTX
M
ea
n
 p
er
ce
n
t 
ch
an
g
e 
fr
o
m
b
as
el
in
e 
± 
S
E
Week 104 Endpoint
*
*
*
*
**
0
−10
−20
−30
−40
−50
−60
Baseline Week 13 Week 26 Week 52
Visit
Serum BAP
M
ea
n
 p
er
ce
n
t 
ch
an
g
e 
fr
o
m
b
as
el
in
e 
± 
S
E
Week 104 Endpoint
Therapeutics and Clinical Risk Management 2013:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
401
eliminating fasting with oral administration of bisphosphonates
35 mg DR weekly in a “noninferiority” test27 during the first 
year of a 2-year study.28 The “noninferiority” or “bridging” 
investigational approach has been used as a realistic substitute 
for mandatory antifracture studies involving approved daily 
oral bisphosphonate regimens when seeking approval for new 
intermittent administration (weekly or monthly regimens). 
The requirement in these cases has been bone mineral density 
(BMD) and bone turnover marker comparisons with the daily 
oral regimens and proof of “noninferior” outcomes. Fracture 
data are being collected as adverse effects.28
In total, 767 postmenopausal osteoporotic women with 
lumbar spine or total hip BMD corresponding to a T-score 
of −2.5 or lower or a T-score of −2.0 or lower with at 
least one prevalent vertebral fracture (T4–L4) completed 
12 months of the study. They had been allocated to one 
of three groups, two of them treated with once-weekly 
risedronate 35 mg DR either at least 30 minutes before 
(delayed-response before breakfast [DRBB], n=258) or 
immediately following breakfast (delayed-response fol-
lowing breakfast [DRFB], n=252) and the third one treated 
with the established regimen of 5 mg risedronate IR daily 
before breakfast (n=257) according to US Food and Drug 
Administration requirements.
The percent change from baseline in lumbar spine BMD 
was the primary end point. At the end of year one, the mean 
percent changes (increase) in BMD and bone turnover mark-
ers (decrease) were similar across groups. The occurrence 
of new incident morphometric vertebral fracture was very 
low and remarkably similar in the three groups. Overall, the 
efficacy of once-weekly risedronate 35 mg DR administered 
before or following breakfast was noninferior to that of rise-
dronate 5 mg IR daily. The same pattern was observed in the 
adverse effects/tolerability profile of once-weekly risedronate 
35 mg DR, with no significant differences between groups. 
Participants dropped out of the study in similar proportions 
across treatment groups. This is not an unexpected finding 
in randomized controlled trials, and may not be interpreted 
as nonimproved adherence in the once-weekly risedronate 
35 mg DR group. The incidence of upper gastrointestinal 
adverse events (upper abdominal pain) in the DRBB group 
and lower gastrointestinal adverse events (mild to moder-
ate diarrhea) in the DRFB group were numerically but not 
statistically higher. Small transient decreases in serum cal-
cium provoking reciprocal changes in total PTH (1-84) were 
recorded in the first few weeks of treatment in the groups 
receiving DR-EDTA, but ran their course without causing 
any clinical symptomatology.
A total of 722 participants completed 2 years of 
treatment.29 Both groups receiving weekly DR risedronate 
demonstrated BMD increases at the lumbar spine and total 
hip similar to or greater than that with the risedronate 5 mg 
IR daily dose group (Figure 5A). Decreases in bone turnover 
markers were similar or significantly lower in the weekly 
risedronate DR groups (Figure 5B). The noninferiority 
of risedronate DR, further supported by bone histomorpho-
metric data (the “gold standard” in assessing bone structure 
and function). After 2 years of treatment, bone-forming 
activity (presence of double tetracycline label) was evident 
in all 45 samples examined.
Histomorphometric measurements (static and dynamic) 
and parameters of bone mineralization were similar across 
treatment groups. These findings are in line with those 
reported after 1, 3, and 5 years of treatment with 5 mg 
risedronate IR daily in postmenopausal women, providing 
assurance that the weekly 35 mg risedronate DR does not 
cause excessive reduction of bone turnover. In patients treated 
with other antiresorptive medications, such as alendronate or 
denosumab (antibody to RANK ligand), tetracycline labels 
have been hard to find in many subjects.30,31 Finally, new 
incident morphometric vertebral fractures were not signifi-
cantly different between the DR and IR groups (five in the 
IR daily group, two in the DRFB weekly group, and six in 
the DRBB weekly group).
Conclusion
The DR formulation of risedronate has simplified the dosing 
regimen for bisphosphonates without compromising clinical 
efficacy, and probably improving it, based on BMD evidence. 
Avoiding the inconvenience of fasting should motivate 
osteoporotic patients to take their treatment for longer and 
therefore may improve poor adherence rates of bisphospho-
nate use. Further studies are required to confirm this.
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